Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07197762 · ClinicalTrials.gov registry record · Phase 4
MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults
A Phase 4 study of Neisseria Meningitidis, sponsored by Emory University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 125
- Enrollment target
- 2
- Study locations
NCT07197762 is a Phase 4 study of Neisseria Meningitidis that is actively recruiting participants, run by Emory University. The registered enrollment target is 125 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT07197762, a Phase 4 study of Neisseria Meningitidis, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 125 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this clinical trial is to determine the immunogenicity of certain vaccines in protecting against meningitis B (MenB) in young adults who have previously received a different MenB vaccine. The main questions it aims to answer are: * How many participants are protected against four key types of MenB bacteria before and after getting the new vaccine? * How strong is the immune response after vaccination, and how many people show a noticeable boost in immune response?
Conditions Studied
Interventions
- BIOLOGICAL Trumenba
- BIOLOGICAL PENBRAYA
Study Locations (2)
Georgia
- Emory Children's Center-Vaccine Research Clinic - Atlanta
- Hope Clinic - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2025-11-04 |
| Est. Completion | 2026-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07197762
The ClinicalTrials.gov registry entry for NCT07197762 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neisseria Meningitidis appearing as the primary indexed condition, and to 2 interventions - of which Trumenba is the first listed.
NCT07197762 reports 2 study locations spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT07197762 about?
NCT07197762 is a clinical study titled "MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults". The goal of this clinical trial is to determine the immunogenicity of certain vaccines in protecting against meningitis B (MenB) in young adults who have previously received a different MenB vaccine. The main questions it aims to answer are: * How many participants are protected against four key t...
What is the current status of trial NCT07197762?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 125 participants. The study started on 2025-11-04. Estimated completion is 2026-12.
What conditions does trial NCT07197762 study?
This clinical trial studies the following conditions: Neisseria Meningitidis.
What interventions are being tested in trial NCT07197762?
The interventions under investigation include: Trumenba (BIOLOGICAL), PENBRAYA (BIOLOGICAL).
Who is sponsoring clinical trial NCT07197762?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07197762 being conducted?
This trial has 2 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neisseria Meningitidis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age
COMPLETED · Phase 3
-
Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.